What changed
$RVMD — AVOID 📊 | 6 MONTHS THESIS
🎯 Q2 2026 | EPS $-1.90 vs $-1.90 ➖
💡 Consensus expects pipeline success to generate multi-billion-dollar revenues, justifying the $100B valuation. Our variant view is that the market is underappreciating the high failure rate of oncology trials and the competitive landscape.
📉 Reward/risk: 1.5:1
🏢 Business Quality: 7/10
📊 Valuation: rich
🔮 Catalyst: Upcoming Phase 3 readout for RMC-6236 in pancreatic cancer (hypothetical Q3 2026 data)
💰 Entry: $169.51, stop $150, target $200
⚖️ Avoid: RVMD is a high-quality oncology biotech, but the $100B valuation prices in perfection, and the upcoming binary catalyst offers poor risk/reward for a long position at current levels.
📊 Our read: AVOID. Full analysis →
https://stockduty.xyz/s/RVMD0624